Is there a difference in the durability of CR based on the dosage of pembrolizumab used in metastatic melanoma?

In this study, doses of 2mg/kg Q3wks, 10mg/kg Q3wks and 10mg/kg Q2wks were used. What did the majority of these patients in CR receive?

Answer from: Medical Oncologist at Academic Institution

This a great question and highlights the drug dosing and development process of the use of Pembrolizumab in metastatic Melanoma. In Keynote-002, Pembrolizumab was studied in the does of 2mg/kg and 10mg/kg vs chemotherapy and the CR responses were 2 vs 3% in the Pembrolizumab arms. In Key...

Comments

Medical Oncologist at Ralph Lauren Center for Cancer Care and Prevention
That makes sense. Thank you!

Please select the option that best describes you:

Is there a difference in the durability of CR based on the dosage of pembrolizumab used in metastatic melanoma?

Related Questions